ESCRS - The robotic future of gene therapy surgery ;
ESCRS - The robotic future of gene therapy surgery ;

The robotic future of gene therapy surgery

The future of gene therapy surgery will almost inevitably involve the use of robotic systems capable of greater precision and control than current techniques

The robotic future of gene therapy surgery
Dermot McGrath
Dermot McGrath
Published: Tuesday, September 12, 2017
[caption id="attachment_9464" align="alignright" width="1024"] Robert MacLaren[/caption] The future of gene therapy surgery will almost inevitably involve the use of robotic systems that are capable of greater precision and control than current manual techniques, Professor Robert MacLaren FRCOphth, FRCS, said at the Young Retinal Specialist (YOURS) Day. In a talk exploring current and future surgical techniques for delivering gene therapy for choroideremia and other genetic retinal diseases, Prof MacLaren said that the ongoing Robotic Retinal Dissection Device (R2D2) trial will help to develop novel surgical treatments for blindness, such as gene therapy and stem cells. The current trial will involve 12 patients in total, following on from the successful first operation in 2016 in which an epiretinal membrane was removed from the eye of a 70-year-old man with a macular hole, using the device developed by Preceyes BV. The gene therapy approach developed by Prof MacLaren’s team used a small, safe adeno-associated viral (AAV2) vector to carry the missing choroideremia gene into the light-sensing cells in the retina. To inject the virus, the patient’s retina is first detached and then the virus is injected directly into the subretinal space. While doubts have been expressed in some quarters about the long-term effectiveness of gene therapy treatment, Prof MacLaren said that the therapy has been shown to be effective up to at least four years after surgery based on a single injection of the viral vector. This provides the strongest evidence so far in humans that the effects of gene therapy are potentially permanent and could therefore provide a single treatment cure for many types of inherited blindness, including retinitis pigmentosa and age-related macular degeneration.
Latest Articles
From Lab to Life: Corneal Repair Goes Cellular

Long-awaited cellular therapies for corneal endothelial disease enter the clinic.

Read more...

Balancing Innovation and Safety

Ensuring access to advanced cell therapies amid regulatory overhaul.

Read more...

With Eyes on Its Future, ESCRS Celebrates Its Past

Winter Meeting offers opportunities to experiment with new concepts and formats.

Read more...

Piecing Together a Solution

What is the best use of robotics and AI in cataract and refractive surgery?

Read more...

Advances in Toric IOL Alignment

Biomorphometric approaches offer high precision and increase efficiency.

Read more...

Library of Short Videos Complements Educational Offerings

Read more...

Tackling Waste in Retinal Surgery

Reducing waste from intravitreal injections is an achievable goal.

Read more...

The Modern Era of Refractive Surgery

New technologies for screening and treatment qualify more patients for intervention.

Read more...

Monofocal Plus Finding the Balance

Enhanced monofocals may be the future standard of care in cataract patients.

Read more...

Growing Options Optimise Outcomes in Cataract Surgery

Understanding the promise and potential problems of AI-based IOL formulas.

Read more...

;